Literature DB >> 21190050

High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review.

R Carron1, V Fraix, C Maineri, E Seigneuret, B Piallat, P Krack, P Pollak, A L Benabid, Stéphan Chabardès.   

Abstract

In advanced Parkinson's disease, several therapeutical option including not only lesional surgery (VIM, GPi) and deep brain stimulation (STN, GPi, VIM) but also continuous subcutaneous apomorphine infusion therapy can be proposed to the patient. The choice depends on the hope of the patient, patient's general health condition and the experience and choice of the neurosurgical and neurologist team. Here we report our experience based on 400 STN-DBS cases and we discuss, on the basis of our experience and on the literature, the advantage and disadvantage of DBS strategy as compared with non-surgical option such as continuous subcutaneous apomorphine infusion therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190050     DOI: 10.1007/s00702-010-0556-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  78 in total

1.  Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD.

Authors:  E Lagrange; P Krack; E Moro; C Ardouin; N Van Blercom; S Chabardes; A L Benabid; P Pollak
Journal:  Neurology       Date:  2002-12-24       Impact factor: 9.910

2.  Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease.

Authors:  Alessandro Stefani; Andres M Lozano; Antonella Peppe; Paolo Stanzione; Salvatore Galati; Domenicantonio Tropepi; Mariangela Pierantozzi; Livia Brusa; Eugenio Scarnati; Paolo Mazzone
Journal:  Brain       Date:  2007-01-24       Impact factor: 13.501

3.  Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.

Authors:  V Fraix; J-L Houeto; C Lagrange; C Le Pen; P Krystkowiak; D Guehl; C Ardouin; M-L Welter; F Maurel; L Defebvre; A Rougier; A-L Benabid; V Mesnage; M Ligier; S Blond; P Burbaud; B Bioulac; A Destée; P Cornu; P Pollak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

Review 4.  Thalamotomy for movement disorders.

Authors:  K J Burchiel
Journal:  Neurosurg Clin N Am       Date:  1995-01       Impact factor: 2.509

5.  Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease.

Authors:  P Krack; P Pollak; P Limousin; D Hoffmann; J Xie; A Benazzouz; A L Benabid
Journal:  Brain       Date:  1998-03       Impact factor: 13.501

6.  Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson's disease.

Authors:  K Dujardin; L Defebvre; P Krystkowiak; S Blond; A Destée
Journal:  J Neurol       Date:  2001-07       Impact factor: 4.849

Review 7.  Postoperative management of subthalamic nucleus stimulation for Parkinson's disease.

Authors:  Paul Krack; Valérie Fraix; Alexandre Mendes; Alim-Louis Benabid; Pierre Pollak
Journal:  Mov Disord       Date:  2002       Impact factor: 10.338

Review 8.  The effect of deep brain stimulation on quality of life in movement disorders.

Authors:  A Diamond; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

9.  Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.

Authors:  T R K Varma; S H Fox; P R Eldridge; P Littlechild; P Byrne; A Forster; A Marshall; H Cameron; K McIver; N Fletcher; M Steiger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

Review 10.  Deep brain stimulation for parkinsonian gait disorders.

Authors:  Andres M Lozano; Brian J Snyder
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

View more
  1 in total

Review 1.  Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review.

Authors:  Hao Xu; Feng Zheng; Boris Krischek; Wanhai Ding; Chi Xiong; Xin Wang; Chaoshi Niu
Journal:  J Int Med Res       Date:  2017-07-12       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.